ArticleStem cells international2026
FOXP1 Promotes Spermatogonial Stem Cell Proliferation by Transcriptionally Repressing GSK3B to Activate the Wnt/β-Catenin Signaling Pathway.
Article in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nonobstructive azoospermia (NOA) is characterized by impaired spermatogenesis, yet the molecular mechanisms regulating spermatogonial stem cells (SSCs) in NOA remain unclear. Forkhead box protein P1 (FOXP1), a transcription factor implicated in cell proliferation and differentiation, may play a critical role in SSC function. Methods: Testicular tissues from OA and NOA patients were examined for FOXP1 expression using reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC). Cell viability, proliferation, and apoptosis were assessed by CCK-8, EdU, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays. The interaction between the FOXP1 and GSK3B promoter was analyzed via bioinformatics, chromatin immunoprecipitation, and luciferase reporter assays. Western blotting evaluated Wnt/β-catenin pathway activation. The role of this pathway was further confirmed by LiCl treatment in FOXP1-silenced SSCs. Results: FOXP1 was downregulated in NOA samples displaying defective spermatogenesis. FOXP1 knockdown inhibited SSC viability and proliferation while promoting apoptosis. Mechanistically, FOXP1 bound directly to the GSK3B promoter, repressing its transcription. Silencing FOXP1 increased GSK3B expression and suppressed Wnt/β-catenin signaling. Activation of Wnt/β-catenin by LiCl reversed the detrimental effects of FOXP1 knockdown on SSCs. Conclusion: FOXP1 positively regulates SSC proliferation and survival by transcriptionally repressing GSK3B and maintaining Wnt/β-catenin signaling. These findings highlight that the FOXP1-GSK3B-Wnt/β-catenin signaling axis plays an essential role in maintaining SSC homeostasis and spermatogenic function and provides novel mechanistic insights into the molecular pathogenesis of NOA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.